Last Updated on October 17, 2024 by The Health Master
Zydus Cadila has received the final approval from the US Food and Drug Administration (FDA) to market mesalamine suppositories for rectal use, (US RLD – Canasa) 1000 mg.
The drug is used to treat ulcerative proctitis, a type of bowel disease.
It is an aminosalicylate anti-inflammatory drug and believed to work by blocking the production of certain natural chemicals that may cause pain and swelling.
Also read: Zydus Cadila gets USFDA nod for Isosorbide Dinitrate tablets, Desonide Cream
This will be manufactured at the group’s topical manufacturing facility at Ahmedabad.
The group has 280 approvals and has so far filed over 386 ANDAs since the commencement of the filing process in FY 2003-04.
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
